Biogen Canada is proud to announce that it has been certified as a Great Place to Work® (GPTW) and named to the 2020 list of Best WorkplacesTM in Healthcare.
Pioneers in Neuroscience
Time is of the essence when it comes to preserving motor neuron function in SMA. Early diagnosis and management of this debilitating neurodegenerative condition which is the leading cause of genetic death in infants is crucial. We are proud to have contributed to the newborn screening pilot study at CHEO to lay the groundwork for adding SMA to routine newborn screening panels.
SMA Awareness Month is a time for the entire SMA community to come together and raise awareness to improve outcomes for patients across Canada.
Stepping up to support Canadian communities during the COVID-19 pandemic
The impact of the COVID-19 pandemic is being felt around the world and by so many. More than ever, our communities need us and are counting on our support. This is the rationale behind the Biogen Foundation $10M global commitment to address the immediate needs of communities and hospital systems.
TO PATIENTS, HEALTHCARE PROVIDERS, PARTNERS, AND OUR COMMUNITY
As the novel coronavirus (COVID-19) outbreak evolves in Canada and around the world, the health and safety of all those who are impacted in any way is our utmost concern.
90 Burnhamthorpe Road West
Suite 1100
Mississauga, Ontario
Canada
L5B 3C3
General Information
Phone: +1 866 359 2502 or +1 905 804 1444
Fax: +1 905 897 3222
Email: CanadaGeneral.Mailbox@biogen.com

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.

We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.